Merck
CN
  • Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Uncoupling angiogenesis and inflammation in peripheral artery disease with therapeutic peptide-loaded microgels.

Biomaterials (2014-08-27)
Angela L Zachman, Xintong Wang, Jason M Tucker-Schwartz, Sean T Fitzpatrick, Sue H Lee, Scott A Guelcher, Melissa C Skala, Hak-Joon Sung
摘要

Peripheral artery disease (PAD) is characterized by vessel occlusion and ischemia in the limbs. Treatment for PAD with surgical interventions has been showing limited success. Moreover, recent clinical trials with treatment of angiogenic growth factors proved ineffective as increased angiogenesis triggered severe inflammation in a proportionally coupled fashion. Hence, the overarching goal of this research was to address this issue by developing a biomaterial system that enables controlled, dual delivery of pro-angiogenic C16 and anti-inflammatory Ac-SDKP peptides in a minimally-invasive way. To achieve the goal, a peptide-loaded injectable microgel system was developed and tested in a mouse model of PAD. When delivered through multiple, low volume injections, the combination of C16 and Ac-SDKP peptides promoted angiogenesis, muscle regeneration, and perfusion recovery, while minimizing detrimental inflammation. Additionally, this peptide combination regulated inflammatory TNF-α pathways independently of MMP-9 mediated pathways of angiogenesis in vitro, suggesting a potential mechanism by which angiogenic and inflammatory responses can be uncoupled in the context of PAD. This study demonstrates a translatable potential of the dual peptide-loaded injectable microgel system for PAD treatment.

材料
货号
品牌
产品描述

Sigma-Aldrich
四氢呋喃, anhydrous, ≥99.9%, inhibitor-free
Sigma-Aldrich
四氢呋喃, inhibitor-free, suitable for HPLC, ≥99.9%
Sigma-Aldrich
二氯甲烷, anhydrous, ≥99.8%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
四氢呋喃, anhydrous, contains 250 ppm BHT as inhibitor, ≥99.9%
Sigma-Aldrich
甲苯, anhydrous, 99.8%
Sigma-Aldrich
二氯甲烷, suitable for HPLC, ≥99.8%, contains amylene as stabilizer
Sigma-Aldrich
二氯甲烷, contains 40-150 ppm amylene as stabilizer, ACS reagent, ≥99.5%
Sigma-Aldrich
甲苯, ACS reagent, ≥99.5%
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, ACS reagent, ≥99.0%
Sigma-Aldrich
二氯甲烷, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%, contains 50-150 ppm amylene as stabilizer
Sigma-Aldrich
甲苯, suitable for HPLC, 99.9%
Sigma-Aldrich
甲苯, HPLC Plus, for HPLC, GC, and residue analysis, ≥99.9%
Sigma-Aldrich
二氯甲烷, puriss. p.a., ACS reagent, reag. ISO, ≥99.9% (GC)
Supelco
甲苯, analytical standard
Supelco
二氯甲烷, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Sigma-Aldrich
四氢呋喃, contains 250 ppm BHT as inhibitor, puriss. p.a., ACS reagent, reag. Ph. Eur., ≥99.9%
Supelco
甲苯, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
二氯甲烷, analytical standard
Sigma-Aldrich
二氯甲烷, puriss., meets analytical specification of Ph. Eur., NF, ≥99% (GC)
Sigma-Aldrich
四氢呋喃, ReagentPlus®, ≥99.0%, contains 250 ppm BHT as inhibitor
Supelco
四氢呋喃, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
四氢呋喃, ACS reagent, ≥99.0%, contains 250 ppm BHT as inhibitor
Sigma-Aldrich
甲苯, Laboratory Reagent, ≥99.3%
Supelco
残留溶剂-甲苯, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
四氢呋喃, analytical standard
Sigma-Aldrich
二氯甲烷, ACS reagent, ≥99.5%, contains 40-150 ppm amylene as stabilizer
Supelco
四氢呋喃, Selectophore, ≥99.5%
Sigma-Aldrich
正己酸乙酯, ≥99%
Sigma-Aldrich
正己酸乙酯, ≥98%, FCC, FG